Literature DB >> 9010981

Always more "setrons": how many do we need?

M S Aapro.   

Abstract

Mesh:

Substances:

Year:  1997        PMID: 9010981     DOI: 10.1007/bf01681952

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  10 in total

1.  Radiotherapy and drugs: 'setrons' once again.

Authors:  M S Aapro
Journal:  Ann Oncol       Date:  1996-08       Impact factor: 32.976

Review 2.  Innovative approaches in the treatment of emesis.

Authors:  S M Grunberg
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

Review 3.  Standard treatment of chemotherapy-induced emesis.

Authors:  D Warr
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

4.  A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Authors:  B Chevallier; P Cappelaere; T Splinter; M Fabbro; J L Wendling; L Cals; G Catimel; M Giovannini; D Khayat; P Bastit; N Claverie
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

5.  Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.

Authors:  E A Perez; R M Navari; H G Kaplan; R J Gralla; S M Grunberg; R H Palmer; D Fitts
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

6.  Dose-finding study of oral metopimazine.

Authors:  J Herrstedt; T Sigsgaard; H R Angelo; J P Kampmann; M Hansen
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

7.  The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  G Marini; S Murray; A Goldhirsch; R D Gelber; M Castiglione-Gertsch; K N Price; M H Tattersall; C M Rudenstam; J Collins; J Lindtner; F Cavalli; H Cortés-Funes; A Gudgeon; J F Forbes; E Galligioni; A S Coates; H J Senn
Journal:  Ann Oncol       Date:  1996-03       Impact factor: 32.976

8.  Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.

Authors:  D Osoba; D G Warr; M I Fitch; L Nakashima; B Warren
Journal:  Can J Oncol       Date:  1995-09

9.  Plasma levels of peptide YY correlate with cisplatin-induced emesis in dogs.

Authors:  M R Perry; J Rhee; W L Smith
Journal:  J Pharm Pharmacol       Date:  1994-07       Impact factor: 3.765

10.  Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.

Authors:  V Kirchner; M Aapro; P Alberto; P O'Grady; B Busch; M Boyce
Journal:  Ann Oncol       Date:  1993-06       Impact factor: 32.976

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.